Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clearing up the p16INK4a-p14/p19ARF imbroglio?].

C J Larsen1

  • 1Laboratoire d'oncologie moléculaire, IBMIG, 40, avenue du Recteur-Pineau, 86022, Poitiers. c.j.larsen@chu-poitiers.fr

Bulletin Du Cancer
|December 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A mutation suppressing a sumoylation site in the MITF transcriptional regulator predisposes to melanoma and renal carcinoma].

Bulletin du cancer·2012
Same author

The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

British journal of cancer·2006
Same author

Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2005
Same author

Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.

Journal of neuro-oncology·2004
Same author

Topoisomerase II alpha and telomerase expression in papillary thyroid carcinomas.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2004
Same author

[Peutz-Jegher syndrome: the guilty speak].

Bulletin du cancer·2001
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

The CDKN2/MTS1 locus is key to understanding cancer. In mice, inactivating p16INK4a is vital for carcinogen-induced tumors, while insufficient ARF protein dosage may also promote tumorigenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The CDKN2/MTS1 locus is critical for understanding cell cycle deregulation in cancer.
  • The distinct roles of p16INK4a and p14/p19ARF (ARF) proteins from this locus are complex due to gene structure.
  • Previous studies have not fully elucidated the combined functions of p16INK4a and ARF.

Purpose of the Study:

  • To investigate the specific roles of p16INK4a and ARF proteins in tumor development.
  • To clarify the contribution of p16INK4a inactivation to carcinogen-induced tumors.
  • To assess the impact of ARF dosage on tumor susceptibility in mice.

Main Methods:

  • Inactivation of the p16INK4a gene in mouse models.
  • Analysis of tumor development in mice with altered p16INK4a and ARF gene status.

Related Experiment Videos

  • In vitro studies on senescence, immortalization, and oncogenic ras transformation.

    • Main Results:

    • Inactivation of both p16INK4a alleles in mice led to various tumors.
    • Reduced functional copies of ARF increased tumor susceptibility in p16INK4a-deficient mice.
    • ARF controls senescence, immortalization, and ras-driven transformation in vitro.
    • p16INK4a inactivation is essential for carcinogen-induced tumor formation.

    Conclusions:

    • p16INK4a inactivation is crucial for carcinogen-induced tumorigenesis in mice.
    • ARF plays a significant role in tumor suppression, with dosage affecting susceptibility.
    • Understanding the interplay between p16INK4a and ARF is vital for cancer research.